Education
About Us
Working with TipRanks
Follow Us
Champions Oncology (CSBR)
:CSBR
Top Page
Champions Oncology
(NASDAQ:CSBR)
Rating:49Neutral
Price Target:―
Champions Oncology (CSBR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$92.72M
Dividend YieldN/A
Average Volume (3M)36.86K
Price to Earnings (P/E)20.7
Beta (1Y)0.29
Revenue Growth13.54%
EPS GrowthN/A
CountryUS
Employees210
SectorHealthcare
Sector Strength49
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.07
Shares Outstanding13,777,170
10 Day Avg. Volume20,837
30 Day Avg. Volume36,856
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue1.62
Enterprise Value/Gross Profit3.10
Enterprise Value/Ebitda11.23
Forecast
1Y Price Target
$12.00Price Target Upside78.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Champions Oncology Business Overview & Revenue Model
Company DescriptionChampions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
How the Company Makes MoneyChampions Oncology generates revenue through its personalized oncology solutions and collaboration with pharmaceutical companies. Its key revenue streams include the sale of its proprietary TumorGraft Technology Platform, which facilitates the creation of personalized cancer treatment plans by implanting human tumors in mice for drug testing. Additionally, the company earns income from its drug discovery and development services, which include preclinical studies and clinical trials. Strategic partnerships and collaborations with major pharmaceutical companies further bolster its earnings by providing opportunities for joint research and development projects.
Champions Oncology Earnings Call Summary
Earnings Call Date:Jul 23, 2025
(Q4-2025)
| % Change Since: |
Next Earnings Date:Sep 10, 2025
Earnings Call Sentiment Positive
The earnings call highlights a successful fiscal year 2025 with record revenue, a return to profitability, and strategic developments like data licensing and new service platforms. However, the fourth quarter showed some weaknesses with a decline in revenue and gross margin. Despite these challenges, the overall sentiment is positive, bolstered by a strong cash position and strategic growth initiatives.Q4-2025 Updates
Positive Updates
Record Revenue Growth
Champions Oncology reported a record total revenue of $57 million for fiscal year 2025, representing a 14% increase from the previous year.
Return to Profitability
The company returned to profitability with an adjusted EBITDA of $7.1 million, a significant improvement from the adjusted EBITDA loss of $3.9 million in fiscal 2024.
Successful Data Licensing Deals
Champions Oncology closed its inaugural data licensing deal in Q3 and several smaller transactions in the recent quarter, contributing $4.7 million to revenue.
Launch of Radiopharmaceutical Services Platform
The company successfully launched a radiopharmaceutical services platform, enhancing its offerings with integrated workflows and collaborations with pharma and biotech partners.
Strong Cash Position
The company ended the year with $9.8 million in cash, up from $2.6 million the previous year, and remains debt-free.
Improved Gross Margins
Gross margin expanded to 50%, up from 42% last year, driven by high-margin data revenue and operational efficiencies.
Negative Updates
Q4 Revenue Decline
Fourth quarter revenue was $12.1 million, a decline from $14 million in the same quarter the previous year.
Decreased Gross Margin in Q4
The gross margin for Q4 was 41%, down from 48% in Q4 2024, due to lower revenue on a relatively unchanged cost base.
Operating Loss in Q4
The company reported a GAAP operating loss of $2 million for the fourth quarter, compared to a loss of $200,000 in 2024.
Company Guidance
During the Champions Oncology Fourth Quarter Fiscal Year 2025 Earnings Call, the company reported a significant turnaround with a 14% increase in total revenue to $57 million, up from $50.2 million the previous year. This growth was driven by a 4% rise in research services revenue to $52.3 million and a $4.7 million contribution from data licensing deals. The company's adjusted EBITDA swung to a positive $7.1 million from a loss of $3.9 million in fiscal 2024, aided by disciplined cost execution and high-margin data revenue. Despite a weaker fourth quarter with $12.1 million in revenue and a GAAP operating loss of $2 million, Champions Oncology maintained a gross margin of 41% and ended the year with $9.8 million in cash. The company launched a new radiopharmaceutical services platform and emphasized strategic investments in their data business, anticipating continued growth in fiscal 2026.Champions Oncology Financial Statement Overview
Summary
Champions Oncology's financial statements depict a company facing significant challenges in revenue stability and cash management, despite some improvements in equity and net income. The high leverage and inconsistent profit margins reflect potential risks, while cash flow issues underscore liquidity concerns. Overall, the company is in a transitional phase, showing both vulnerabilities and some recovery indicators.Income Statement
The company exhibits a volatile income statement with a negative gross profit margin in TTM, indicating more costs than revenue. Despite a positive net income in TTM, the revenue growth rate is negative, showing declining sales over time. Margins are inconsistent, with significant fluctuations in EBIT and EBITDA margins. The overall income statement suggests instability in revenue generation and cost management.40
Negative
Balance Sheet
The balance sheet reveals a concerning debt-to-equity ratio, indicating high leverage. However, the TTM data shows improved stockholders' equity, suggesting a recovery trend. ROE is positive in TTM, reflecting recent profitability. The equity ratio remains low, indicating potential financial risk due to dependence on liabilities. The balance sheet points to a moderate risk profile with some signs of recovery.45
Neutral
Cash Flow
Cash flow analysis shows negative free cash flow growth in TTM, reflecting cash management challenges. The operating cash flow to net income ratio is negative, indicating cash outflows even with positive net income. This trend suggests problems in converting earnings into cash. The cash flow statement highlights liquidity challenges and inefficiencies in cash operations.35
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 50.16M | 53.87M | 49.11M | 41.04M |
| Gross Profit | -28.39M | 20.75M | 24.34M | 25.48M | 19.57M |
| EBITDA | 4.55M | -5.05M | -2.07M | 2.23M | 366.00K |
| Net Income | 4.70M | -7.28M | -5.33M | 548.00K | 362.00K |
Balance Sheet | |||||
| Total Assets | 32.34M | 26.13M | 34.31M | 35.38M | 27.59M |
| Cash, Cash Equivalents and Short-Term Investments | 9.79M | 2.62M | 10.12M | 9.01M | 4.69M |
| Total Debt | 6.11M | 7.43M | 8.60M | 9.47M | 9.60M |
| Total Liabilities | 28.57M | 28.04M | 29.68M | 26.28M | 20.16M |
| Stockholders Equity | 3.77M | -1.90M | 4.64M | 9.10M | 7.43M |
Cash Flow | |||||
| Free Cash Flow | 7.00M | -6.97M | 1.08M | 4.11M | -4.96M |
| Operating Cash Flow | 7.39M | -6.14M | 3.96M | 6.50M | -1.68M |
| Investing Cash Flow | -389.00K | -836.00K | -2.87M | -2.38M | -3.17M |
| Financing Cash Flow | 170.00K | -527.00K | 11.00K | 207.00K | 1.20M |
Champions Oncology Technical Analysis
Negative
6.73
Price Trends
7.36
Negative
7.10
Negative
7.72
Negative
Market Momentum
0.01
Negative
46.38
Neutral
39.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSBR, the sentiment is Negative. The current price of 6.73 is above the 20-day moving average (MA) of 6.72, below the 50-day MA of 7.36, and below the 200-day MA of 7.72, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 46.38 is Neutral, neither overbought nor oversold. The STOCH value of 39.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CSBR.
Champions Oncology Risk Analysis
Champions Oncology disclosed 30 risk factors in its most recent earnings report. Champions Oncology reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Champions Oncology Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $129.17M | 21.89 | 15.99% | ― | 62.79% | ― | |
51 Neutral | $7.83B | -0.15 | -40.10% | 2.29% | 21.46% | -2.01% | |
49 Neutral | $92.72M | 20.71 | 503.05% | ― | 13.54% | ― | |
49 Neutral | $96.31M | ― | -61.14% | ― | ― | -2.11% | |
43 Neutral | $108.69M | ― | -88.95% | ― | ― | -553.86% | |
36 Underperform | $98.14M | ― | -41.66% | ― | ― | -8.91% | |
| ― | $165.55M | ― | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
CSBR
Champions Oncology
6.60
2.42
57.89%
SAVA
Cassava Sciences
2.31
-26.20
-91.90%
PLX
Protalix
1.62
0.71
78.02%
ATOS
Atossa Therapeutics
0.78
-0.59
-43.07%
ANIX
Anixa Biosciences
2.95
-0.37
-11.14%
ACTU
Actuate Therapeutics, Inc.
8.19
0.06
0.74%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.